Addressing Unmet Needs in the PAH Landscape

Author(s):

Marius Hoeper, MD

Marius Hoeper, MD, describes the role clinicians can play in advocating for health care system reforms that could address the economic implications of PAH and discusses the key unmet needs in the PAH treatment landscape.

EP: 1.Evolving Guidelines for PAH Treatment

EP: 2.New Therapeutic Frontiers in PAH

EP: 3.Addressing Unmet Needs and Disease Progression Challenges in Pulmonary Arterial Hypertension Management

EP: 4.Overcoming Limitations and Barriers Associated with Treating Pulmonary Arterial Hypertension

EP: 5.Breaking Down the PAH Cost Burden

EP: 6.A New Era in PAH Treatment?

EP: 7.Clinical Evidence for Emerging PAH Therapies

EP: 8.Integrating New PAH Therapies into Clinical Practice

EP: 9.Optimizing Complex Pulmonary Arterial Hypertension Care: Enhancing Adherence and Outcomes

EP: 10.FDA Approves Sotatercept for Pulmonary Arterial Hypertension

EP: 11.Overcoming Barriers to Better Patient Outcomes in PAH

EP: 12.Advancing Pulmonary Arterial Hypertension Care: Overcoming Challenges in Special Populations and Exploring Innovative Approaches

EP: 13.Optimizing PAH Care Delivery for Better Outcomes

Now Viewing

EP: 14.Addressing Unmet Needs in the PAH Landscape

Video content above is prompted by the following questions:

What role can clinicians play in advocating for integrated care delivery models, value-based payment strategies, or other health care system reforms that could address the economic implications of pulmonary arterial hypertension (PAH) more effectively?
What are the key unmet needs or challenges related to the management of PAH that you hope will be addressed more comprehensively in the coming years as the treatment landscape evolves with therapies like sotatercept?